Mallinckrodt stock toppled early Tuesday after the Irish biotech guided to a 21%-25% decline in specialty generics sales for 2017, though quarterly sales and profits easily crushed Wall Street’s views. Overall 2017 sales are expected to dip 2%-5% in 2017, indicating $3.23 billion to $3.33 billion.